Intravitreal bevacizumab for the treatment of neovascular glaucoma associated with central retinal artery occlusion

• Published in: Korean journal of ophthalmology Vol. 23; no. 3; pp. 215 - 218
• Main Authors: Sagong, Min, Kim, Jinseon, Chang, Woohyok
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Ophthalmological Society 01.09.2009; 대한안과학회
• Subjects: Aged; Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Bevacizumab; Case Report; Female; Glaucoma, Neovascular - drug therapy; Glaucoma, Neovascular - etiology; Humans; Injections; Male; Middle Aged; Recurrence; Retinal Artery Occlusion - complications; Retreatment; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Vitreous Body; 안과학; Intravitreal bevacizumab; Central retinal artery occlusion; Neovascular glaucoma; Panretinal photocoagulation
• ISSN: 1011-8942; 2092-9382
• DOI: 10.3341/kjo.2009.23.3.215

We report three cases of neovascular glaucoma secondary to central retinal artery occlusion (CRAO) which were effectively managed with intravitreal bevacizumab (IVB) followed by panretinal photocoagulation (PRP). Neovascular glaucoma without peripheral anterior synechiae developed between one and five weeks following CRAO onset. All patients received 0.75 mg (0.03 ml) IVB. In all patients, complete regression of the iris and anterior chamber angle neovascularization was confirmed within one week. PRP was applied two weeks after the injection. The follow-up period was four to seven months (average, five months). Intraocular pressure was controlled in all patients using topical antiglaucoma medications alone. However, one patient experienced a recurrence of neovascularization three months after the initial combination treatment. This patient received another IVB injection and additional PRP, and the recurrent neovascularization resolved. There were no local or systemic adverse events in any patients. Therefore, intravitreal bevacizumab may be an effective adjunct in the treatment of neovascular glaucoma associated with CRAO.